- Home
- AKA vs NLSP Comparison
AKA vs NLSP Comparison
Compare AKA & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKA
- NLSP
- Stock Information
- Founded
- AKA 2018
- NLSP 2015
- Country
- AKA United States
- NLSP Switzerland
- Employees
- AKA N/A
- NLSP N/A
- Industry
- AKA Catalog/Specialty Distribution
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- AKA Consumer Discretionary
- NLSP Health Care
- Exchange
- AKA Nasdaq
- NLSP Nasdaq
- Market Cap
- AKA 251.5M
- NLSP 243.8M
- IPO Year
- AKA 2021
- NLSP 2021
- Fundamental
- Price
- AKA $21.98
- NLSP $5.28
- Analyst Decision
- AKA Buy
- NLSP
- Analyst Count
- AKA 4
- NLSP 0
- Target Price
- AKA $18.75
- NLSP N/A
- AVG Volume (30 Days)
- AKA 11.0K
- NLSP 26.9K
- Earning Date
- AKA 11-06-2024
- NLSP 10-18-2024
- Dividend Yield
- AKA N/A
- NLSP N/A
- EPS Growth
- AKA N/A
- NLSP N/A
- EPS
- AKA N/A
- NLSP N/A
- Revenue
- AKA $555,516,000.00
- NLSP N/A
- Revenue This Year
- AKA $4.07
- NLSP N/A
- Revenue Next Year
- AKA $3.86
- NLSP N/A
- P/E Ratio
- AKA N/A
- NLSP N/A
- Revenue Growth
- AKA N/A
- NLSP N/A
- 52 Week Low
- AKA $4.53
- NLSP $4.08
- 52 Week High
- AKA $33.73
- NLSP $40.60
- Technical
- Relative Strength Index (RSI)
- AKA 49.01
- NLSP 45.46
- Support Level
- AKA $17.20
- NLSP $4.72
- Resistance Level
- AKA $24.40
- NLSP $5.50
- Average True Range (ATR)
- AKA 1.80
- NLSP 0.64
- MACD
- AKA -0.62
- NLSP 0.05
- Stochastic Oscillator
- AKA 52.13
- NLSP 41.67
About AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.